Literature DB >> 33350679

Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature.

Anne-Laure Desage1, Wafa Bouleftour1, Romain Rivoirard1, Nicolas Magne2, Olivier Collard1, Pierre Fournel1, Claire Tissot1.   

Abstract

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become part of cancer treatments. Their main side effects are immune-related adverse events (irAEs). So far, there has been no recommendation regarding routine vaccinations during ICIs treatment. Clinicians are aware of the risk of irAEs increases in this specific situation. The aim of this review of literature is to summarize the main studies about vaccination and ICIs interactions.
METHODS: A systematic assessment of literature articles was performed by searching in PubMed (MEDLINE), and major oncology meeting following PRISMA guidelines.
RESULTS: This review highlights the lack of literature. Indeed, most of the studies published were about influenza vaccination. Vaccination for patients under ICIs causes a humoral response and seems to be associated with an increase rate of seroconversion. Interestingly vaccination may provoke irAEs in ICIs-treated patients. So far, inactivated vaccines have not been contraindicated during ICI treatment.
CONCLUSION: Larger prospective studies are needed in order to define a consensus on the use of vaccines under immunotherapy.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33350679     DOI: 10.1097/COC.0000000000000788

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  10 in total

1.  Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.

Authors:  Makoto Hibino; Kiyoaki Uryu; Takayuki Takeda; Yusuke Kunimatsu; Shinsuke Shiotsu; Junji Uchino; Soichi Hirai; Tadaaki Yamada; Asuka Okada; Yoshikazu Hasegawa; Osamu Hiranuma; Yusuke Chihara; Riko Kamada; Shunichi Tobe; Kazunari Maeda; Shigeto Horiuchi; Tetsuri Kondo; Koichi Takayama
Journal:  J Thorac Oncol       Date:  2022-06-22       Impact factor: 20.121

2.  COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety.

Authors:  Seyed Alireza Javadinia; Kimia Alizadeh; Mohammad-Shafi Mojadadi; Fateme Nikbakht; Farzaneh Dashti; Maryam Joudi; Hadi Harati; James S Welsh; Seyed Amir Farahmand; Fahimeh Attarian
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-02       Impact factor: 6.055

3.  Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.

Authors:  Barliz Waissengrin; Abed Agbarya; Esraa Safadi; Hagit Padova; Ido Wolf
Journal:  Lancet Oncol       Date:  2021-04-01       Impact factor: 41.316

Review 4.  Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.

Authors:  Manit K Gundavda; Kaival K Gundavda
Journal:  Curr Treat Options Oncol       Date:  2021-09-13

Review 5.  Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.

Authors:  C Corti; G Antonarelli; F Scotté; J P Spano; J Barrière; J M Michot; F André; G Curigliano
Journal:  Ann Oncol       Date:  2021-10-28       Impact factor: 32.976

Review 6.  Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.

Authors:  Adithya Chennamadhavuni; Laith Abushahin; Ning Jin; Carolyn J Presley; Ashish Manne
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 8.786

7.  COVID-19  vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.

Authors:  Marek Jutel; Maria J Torres; Oscar Palomares; Cezmi A Akdis; Thomas Eiwegger; Eva Untersmayr; Domingo Barber; Magdalena Zemelka-Wiacek; Anna Kosowska; Elizabeth Palmer; Stefan Vieths; Vera Mahler; Walter G Canonica; Kari Nadeau; Mohamed H Shamji; Ioana Agache
Journal:  Allergy       Date:  2022-03-18       Impact factor: 14.710

Review 8.  Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis.

Authors:  Maria A Lopez-Olivo; Valeria Valerio; Aliza R Karpes Matusevich; Marianela Brizio; Michelle Kwok; Yimin Geng; Maria E Suarez-Almazor; Ines Colmegna
Journal:  Vaccines (Basel)       Date:  2022-07-27

Review 9.  Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches.

Authors:  Alexander Batista-Duharte; Fakhri Hassouneh; Pablo Alvarez-Heredia; Alejandra Pera; Rafael Solana
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

10.  Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?

Authors:  K Hussain; A Kawsar; J Weir; L Au; S Turajlic; J Larkin; L Fearfield
Journal:  Clin Exp Dermatol       Date:  2021-08-13       Impact factor: 4.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.